Donor Immune Cells (TGF-β NK Cells)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Donor Immune Cells (TGF-β NK Cells), covering 2026-03-05 to 2026-03-05. Get the full timeline:
Most recent: Clinical Trial Update: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]